PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-65.77%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-6.04%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-65.74%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-47.67%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-53.82%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
12.14%
Share count expansion well above TRVN's 14.83%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.50%
Diluted share count expanding well above TRVN's 14.83%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-13.29%
Negative OCF growth while TRVN is at 0.79%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-13.04%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24856.69%
Negative 10Y OCF/share CAGR while TRVN stands at 3.44%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-19589.97%
Negative 5Y OCF/share CAGR while TRVN is at 3.44%. Joel Greenblatt would question the firm’s operational model or cost structure.
63.13%
3Y OCF/share CAGR above 1.5x TRVN's 3.44%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-19587.84%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-19245.92%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
62.10%
Positive short-term CAGR while TRVN is negative. John Neff would see a clear advantage in near-term profit trajectory.
30196.53%
Below 50% of TRVN's 99113.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
5954.03%
Below 50% of TRVN's 99113.21%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
827.17%
Below 50% of TRVN's 99113.21%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.14%
Asset growth above 1.5x TRVN's 2.74%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-14.41%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
Our R&D shrinks while TRVN invests at 40.41%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
28.86%
SG&A growth well above TRVN's 37.40%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.